南方医科大学学报2025，Vol.45Issue(5)：969-976,8.DOI:10.12122/j.issn.1673-4254.2025.05.09
参芪补中方通过激活AMPK/SIRT1/PGC-1α改善COPD肺脾气虚证大鼠线粒体功能障碍
Shenqi Buzhong Formula ameliorates mitochondrial dysfunction in a rat model of chronic obstructive pulmonary disease by activating the AMPK/SIRT1/PGC-1α pathway
摘要
Abstract
Objective To explore the mechanism of Shenqi Buzhong(SQBZ)Formula for alleviating mitochondrial dysfunction in a rat model of chronic obstructive pulmonary disease(COPD)in light of the AMPK/SIRT1/PGC-1α pathway.Methods Fifty male SD rat models of COPD,established by intratracheal lipopolysaccharide(LPS)instillation,exposure to cigarette smoke,and gavage of Senna leaf infusion,were randomized into 5 groups(n=10)for treatment with saline(model group),SQBZ Formula at low,moderate and high doses(3.08,6.16 and 12.32 g/kg,respectively),or aminophylline(0.024 g/kg)by gavage for 4 weeks,with another 10 untreated rats as the control group.Pulmonary function of the rats were tested,and pathologies and ultrastructural changes of the lung tissues were examined using HE staining and transmission electron microscopy.The levels of SOD,ATP,MDA,and mitochondrial membrane potential in the lungs were detected using WST-1,colorimetric assay,TBA,and JC-1 methods.Flow cytometry was used to analyze ROS level in the lung tissues,and the protein expression levels of P-AMPKα,AMPKα,SIRTI,and PGC-1α were detected using Western blotting.Results The rat models of COPD showed significantly decreased lung function,severe histopathological injuries of the lungs,decreased pulmonary levels of SOD activity,ATP and mitochondrial membrane potential,increased levels of MDA and ROS,and decreased pulmonary expressions of P-AMPKα,SIRTI,and PGC-1α proteins.All these changes were significantly alleviated by treatment with SQBZ Formula and aminophylline,and the efficacy was comparable between high-dose SQBZ Formula group and aminophylline group.Conclusion SQBZ Formula ameliorates mitochondrial dysfunction in COPD rats possibly by activating the AMPK/SIRT1/PGC-1α pathway.关键词
慢性阻塞性肺疾病/参芪补中方/线粒体功能障碍/线粒体生物发生/AMPK/SIRT1/PGC-1α通路Key words
chronic obstructive pulmonary disease/Shenqi Buzhong Formula/mitochondrial dysfunction/mitochondrial biogenesis/AMPK/SIRT1/PGC-1α pathway引用本文复制引用
张璐,丁焕章,许浩燃,陈珂,许博文,杨勤军,吴迪,童佳兵,李泽庚..参芪补中方通过激活AMPK/SIRT1/PGC-1α改善COPD肺脾气虚证大鼠线粒体功能障碍[J].南方医科大学学报,2025,45(5):969-976,8.基金项目
国家自然科学基金联合重点项目(U20A20398) （U20A20398）
合肥综合性国家科学中心大健康研究院新安医学与中医药现代化研究所"揭榜挂帅"重大突破项目(2023CXMMTCM005) （2023CXMMTCM005）
